Application of human urinary kallidinogenase in preparing medicine for treating diabetic nephropathy

A technique for urinary kininogenase and diabetic nephropathy, which is applied in the field of preparation of drugs for treating diabetic nephropathy, and can solve problems such as the reduction of kininogenase activity and the effect on vascular regulation function

Inactive Publication Date: 2010-11-10
GUANGDONG TECHPOOL BIO-PHARMA CO LTD
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that the activity of kininogenase did not change significantly at 8 weeks after the formation of diabetes, but at 18 weeks, the activity of kininogenase decreased significantly, only 20-25% of the normal control group, seriously affecting its effect on blood vessels. adjustment function

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of human urinary kallidinogenase in preparing medicine for treating diabetic nephropathy
  • Application of human urinary kallidinogenase in preparing medicine for treating diabetic nephropathy
  • Application of human urinary kallidinogenase in preparing medicine for treating diabetic nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1 Preparation of human urinary kininogenase dry powder injection

[0013] Take filter-sterilized human urinary kininogenase 150PNA units, add 7.5 grams of mannitol, 2 grams of dextran 40, and 5 grams of sodium citrate to dissolve, adjust the pH to neutral, add water for injection to 500 ml, sterile filter, divide Put it in 1000 ampoules, and freeze-dry it under aseptic conditions.

Embodiment 2

[0014] Example 2 Preparation of human urinary kininogenase injection

[0015] Take filtered sterilized human urinary kininogenase dissolved in 150 PNA units, adjust the pH to neutral, add water for injection to 500 ml, add sodium chloride to adjust isotonicity, filter aseptically, divide into 1000 ampoules, and obtain.

Embodiment 3

[0016] Example 3 Therapeutic effect of human urinary kallikrein on rats with diabetic nephropathy

[0017] experimental method

[0018] Rat animal model of diabetic nephropathy induced by unilateral nephrectomy plus intraperitoneal injection of streptozotocin (STZ). Select 60 SD rats of 180-220g, male or female, and randomly divide them into 5 groups: sham operation group; DN model group; human urinary kallikrein I group (3.85×10 -3 PNAu); human urinary kininogenase II group (8.75×10 -3 PNAu); human urinary kininogenase III group (17.5×10 -3 PNAu), rats in each treatment group were injected with human urokininogenase into the tail vein after modeling, once a day for 4 consecutive weeks. The sham operation group and the DN model group were given the same volume of saline through the tail vein.

[0019] Observation indicators

[0020] After 4 weeks, the 24-h urine of the rats in each group was collected and stored at -20°C for 24-h urine protein testing. After urination, t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a novel medicine application of human urinary kallidinogenase, i.e. the application of the human urinary kallidinogenase in preparing medicine for treating diabetic nephropathy.

Description

technical field [0001] The present invention relates to the field of medicinal chemistry. Specifically, the present invention relates to a new medical application of human urinary kallikrein, that is, the application of human urinary kallikrein in the preparation of drugs for treating diabetic nephropathy. Background technique [0002] Human Urinary Kallidinogenase (Human Urinary Kallidinogenase) is a refined glycoprotein extracted from the urine of healthy men, with a molecular weight of about 54,000 Daltons. It can activate the conversion of human plasma kininogen into kinin, dilate blood vessels and increase blood flow. Improve blood circulation, and also increase the deformability of red blood cells and inhibit platelet aggregation, prolong recalcification time and improve blood viscosity. The applicant's previous patent application "200610127956.3 Application of Human Urokininogenase in the Preparation of Drugs for Treating Diabetes with Cerebral Infarction" disclosed ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/49A61P13/12A61P3/10
Inventor 傅和亮邹春芽孙铁吴蓉蓉孙莉
Owner GUANGDONG TECHPOOL BIO-PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap